Drug Trial Radar · NCT05015192
Single Ascending Dose Study of NH102 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Aug 12, 2021
Primary completion
Jan 11, 2022
Study completion Jan 11, 2022
Sponsor
- Lead sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as single oral dose at escalating dose levels in healthy participants.
Conditions
- Depression
Interventions
NH102Drug
tablets, orally
PlaceboDrug
tablets, orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events as a measure of safety and tolerabilityTime frame: Baseline up to Day 11
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.